Technology Prognosis

tracking technologies before you have to make a decision

Endari (Pharmaceutical Grade L-Glutamine)

August 1, 2018

Endari (oral pharmaceutical grade L-glutamine) is an amino acid with antioxidant properties indicated to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients 5 years of age and older.  It is a precursor for nicotinamide adenine dinucleotide (NAD), which is deficient in patients with SCD. A definitive mechanism of action is not yet defined, but Endari may benefit patients with SCD by increasing the activity of NAD synthesis, thus countering the oxidant-dependent pathophysiology of sickled red blood cells.